Epredia lancia le stampanti laser a cassetta progettate per migliorare la tracciabilità dei campioni e l'efficienza del laboratorio

Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523),  and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScanTM, a product under development as a medical device designed to support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Avantik, a company specializing in supporting diagnostic labs with their operations, to support distribution of this new device to surgeons after it is on the market.

Skin cancer is the most common group of cancers diagnosed worldwide , and it is estimated that one in five Americans will develop skin cancer in their lifetime . Non-melanoma skin cancers (NMSC) are the most common cancers in the United States, affecting more than 3 million Americans a year . Most surgeries for NMSC are simple excisions, which may result in removal of substantial healthy tissue around the suspected cancer. 

MarginScan™ is being designed to address this challenge by supporting Mohs surgery procedures for skin cancer treatment. Mohs Micrographic Surgery (MMS) is an operative method used to detect the presence or absence of a tumor in the margins of a surgical excision. In an MMS procedure, cancer tissue is excised in stages, then flash-frozen and assessed histologically in an onsite lab until clean margins are obtained. Previously, MMS was the only modality for skin cancer treatment that involved comprehensive margin assessment during a procedure. MarginScan™ is being designed to use an electrical assessment to confirm cancer-free margins without the intraoperative histological assessment. This has the potential to allow for faster excisions that spare more healthy tissue, leading to improved outcomes for both patients and clinicians.

With this agreement, Epredia plans to serve as the primary distribution partner of MarginScan™ and have exclusive distribution rights in the United States. Along with distribution, Epredia plans to be responsible for all marketing and commercial activities related to the launch and sale of MarginScan™. After product launch, Epredia will work closely with Avantik to market and sell the new device to Mohs surgeons.

Under these planned arrangements, after launch, MarginScan™ will be the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow, including slide scanners and printers, cryostats, tissue processors, and consumables such as slides and reagents. In addition to offering MarginScan™, Epredia also has plans to provide consumable products that are used with the device, such as the MarginScan™ electrode and proprietary electrolytic gel used during excisions. 

The two companies anticipate a 2025 U.S. launch for MarginScan™. The planned distribution agreement builds on a previous agreement between NovaScan and PHC Corporation, another subsidiary of PHC Holdings Corporation that is focused on the development and manufacturing of innovative medical testing devices. PHC Holdings Corporation is referred to collectively with its subsidiaries as PHC Group.  

Steven Lynum, President of Epredia, said, “With more than 85 years supporting precision cancer diagnostics, we strive to continuously serve the changing needs of our customers by working with innovative companies like NovaScan to deliver the best solutions. Helping providers make faster, more accurate diagnoses and ultimately improving patient care is what makes this initiative so important.”

Craig Davis, CEO of NovaScan, remarked, “NovaScan is thrilled to be making plans with Epredia to bring MarginScan™ to clinical healthcare providers in the U.S. We will be proud for MarginScan™ to join Epredia’s portfolio of market-leading cancer diagnostics products in the future. We believe that MarginScan™ will play an important role in skin cancer detection and treatment”

Mark Zacur, CEO of Avantik, added, “Our team is continually sourcing the best solutions to expand our portfolio of solutions supporting Mohs clinics with their critical work. We are honored that Epredia selected Avantik as their partner for this planned initiative to bring this breakthrough device to our network of providers and their patients when it is launched.”

---

Su Epredia

Epredia è leader mondiale nel settore della patologia anatomica e fornisce soluzioni complete per la diagnostica oncologica e tissutale di precisione. Grazie a marchi importanti, tra cui Erie Scientific, Menzel-Gläser, Microm, Shandon e Richard-Allan Scientific, il portafoglio di Epredia comprende vetrini per microscopio, strumenti e materiali di consumo. Epredia è stata fondata in seguito all'acquisizione delle attività di anatomia patologica di Thermo Fisher Scientific’da parte di PHC Holdings nel 2019. Epredia è presente nei principali siti di Stati Uniti, Regno Unito, Germania, Svizzera e Cina con un totale di circa 1.200 dipendenti. Epredia è impegnata a realizzare la sua missione di migliorare la vita dei pazienti di tutto il mondo attraverso il potenziamento della diagnostica oncologica. Per ulteriori informazioni su Epredia e i suoi prodotti, visitare il sito www.epredia.com.

Sulla PHC Holdings Corporation (PHC Group)

PHC Holdings Corporation (TSE 6523) è un'azienda sanitaria globale con la missione di contribuire alla salute della società attraverso soluzioni sanitarie che abbiano un impatto positivo e migliorino la vita delle persone. Le sue consociate (indicate collettivamente come PHC Group) comprendono PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford e Wemex. Insieme, queste società sviluppano, producono, vendono e forniscono assistenza per soluzioni di gestione del diabete, soluzioni sanitarie, scienze della vita e diagnostica. Il fatturato netto consolidato di PHC Group’nell'anno fiscale 2022 è stato di 356,4 miliardi di JPY con una distribuzione globale di prodotti e servizi in oltre 125 Paesi.
www.phchd.com

Per ulteriori informazioni, contattare:

Julia Cottrill
PHC Group Corporate Communications
Email: julia.cottrill@phchd.com